DePuy Synthes Sales, Inc. Announces Exclusive Co-Promotional Agreement with Pacira Pharmaceuticals, Inc
January 25, 2017 at 07:30 am
Share
DePuy Synthes Companies announced an exclusive agreement in the U.S. between DePuy Synthes Sales, Inc. and Pacira Pharmaceuticals Inc. to co-promote EXPAREL, a long-lasting, non-opioid, local analgesic administered at the orthopaedic surgical site. The agreement allows DePuy Synthes to promote EXPAREL across its joint reconstruction, spine, sports medicine, and trauma businesses to help with postsurgical patient pain. This will further enhance the company's portfolio and reach in the operating room while also helping hospital customers better achieve their Triple Aim goals of improving clinical outcomes, reducing costs and enhancing patient satisfaction. While opioids have typically been used for the management of orthopaedic postsurgical pain, EXPAREL provides targeted, non-opioid pain control by working right at the site of surgery, allowing for long-lasting pain relief. Reduced pain allows the opportunity for earlier weight bearing and mobilization immediately following surgery, and more patients discharged to home rather than interim care facilities. DePuy Synthes is expected to begin co-promoting EXPAREL in first quarter of 2017.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.